| Classification and Nomenclature of CRISPR-Cas Systems: Where from Here? |
42 |
| EditR: A Method to Quantify Base Editing from Sanger Sequencing |
33 |
| Meet the Anti-CRISPRs: Widespread Protein Inhibitors of CRISPR-Cas Systems |
20 |
| CRISPRdisco: An Automated Pipeline for the Discovery and Analysis of CRISPR-Cas Systems |
19 |
| Allele-Specific CRISPR-Cas9 Genome Editing of the Single-Base P23H Mutation for Rhodopsin-Associated Dominant Retinitis Pigmentosa |
18 |
| Do CRISPR Germline Ethics Statements Cut It? |
17 |
| Transgenerational CRISPR-Cas9 Activity Facilitates Multiplex Gene Editing in Allopolyploid Wheat |
17 |
| Development and Application of Base Editors |
10 |
| Genome Editing B.C. (Before CRISPR): Lasting Lessons from the Old Testament |
9 |
| Nucleic Acid Detection of Plant Genes Using CRISPR-Cas13 |
9 |
| A Type IV-A CRISPR-Cas System in Pseudomonas aeruginosa Mediates RNA-Guided Plasmid Interference In Vivo |
8 |
| Harnessing A Billion Years of Experimentation: The Ongoing Exploration and Exploitation of CRISPR-Cas Immune Systems |
8 |
| The CRISPR Patent Landscape: Past, Present, and Future |
7 |
| High Activity Target-Site Identification Using Phenotypic Independent CRISPR-Cas9 Core Functionality |
7 |
| CRISPR-Directed Gene Editing Catalyzes Precise Gene Segment Replacement In Vitro Enabling a Novel Method for Multiplex Site-Directed Mutagenesis |
6 |
| Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides |
6 |
| Human Germline Genome Editing: An Assessment |
5 |
| Heritable Genome Editing: Who Speaks for Future Children? |
5 |
| Estimating Demand for Germline Genome Editing: An In Vitro Fertilization Clinic Perspective |
5 |
| Selective Maintenance of Multiple CRISPR Arrays Across Prokaryotes |
5 |
| Enabling the Rise of a CRISPR World |
5 |
| Single-Step, High-Efficiency CRISPR-Cas9 Genome Editing in Primary Human Disease-Derived Fibroblasts |
4 |
| Is Enhancement the Price of Prevention in Human Gene Editing? |
4 |
| Expanding the CRISPR Toolbox with ErCas12a in Zebrafish and Human Cells |
4 |
| Three-Component Repurposed Technology for Enhanced Expression: Highly Accumulable Transcriptional Activators via Branched Tag Arrays |
4 |
| CRISPR-Cas9 Causes Chromosomal Instability and Rearrangements in Cancer Cell Lines, Detectable by Cytogenetic Methods |
4 |
| Democratic Governance of Human Germline Genome Editing |
4 |
| Heritable Genome Editing and the Downsides of a Global Moratorium |
4 |
| Societal and Ethical Impacts of Germline Genome Editing: How Can We Secure Human Rights? |
4 |
| The Daunting Economics of Therapeutic Genome Editing |
4 |
| Impact of Genetic Variation on CRISPR-Cas Targeting |
4 |
| Advancing a New Toolkit for Conservation: From Science to Policy |
4 |
| RNA-Guided Recombinase-Cas9 Fusion Targets Genomic DNA Deletion and Integration |
4 |
| VHL Synthetic Lethality Signatures Uncovered by Genotype-Specific CRISPR-Cas9 Screens |
4 |
| Redkmer: An Assembly-Free Pipeline for the Identification of Abundant and Specific X-Chromosome Target Sequences for X-Shredding by CRISPR Endonucleases |
4 |
| Safety of Germline Genome Editing for Genetically Related Future Children as Perceived by Parents |
3 |
| The Importance of a Novel Product Risk-Based Trigger for Gene-Editing Regulation in Food Animal Species |
3 |
| CRISPR-Directed In Vitro Gene Editing of Plasmid DNA Catalyzed by Cpf1 (Cas12a) Nuclease and a Mammalian Cell-Free Extract |
3 |
| CRISPR-Cas9-Mediated Correction of the 1.02 kb Common Deletion in CLN3 in Induced Pluripotent Stem Cells from Patients with Batten Disease |
3 |
| Identification of Guide-Intrinsic Determinants of Cas9 Specificity |
3 |
| Double-Stranded Biotinylated Donor Enhances Homology-Directed Repair in Combination with Cas9 Monoavidin in Mammalian Cells |
3 |
| Prediction of Human Immunodeficiency Virus Type 1 Subtype-Specific Off-Target Effects Arising from CRISPR-Cas9 Gene Editing Therapy |
3 |
| CRISPR-Based Editing Reveals Edge-Specific Effects in Biological Networks |
3 |
| A Simple Combined Use of CRISPR-Cas9 and Cre-LoxP Technologies for Generating Conditional Gene Knockouts in Mammalian Cells |
3 |
| Evolving Regulatory Landscape for Genome-Edited Plants |
2 |
| CRISPRs for Strain Tracking and Their Application to Microbiota Transplantation Data Analysis |
2 |
| Engineering CRISPR-Cas9 RNA-Protein Complexes for Improved Function and Delivery |
2 |
| Genetic Protection Modifications: Moving Beyond the Binary Distinction Between Therapy and Enhancement for Human Genome Editing |
2 |
| Expanding the RNA-Guided Endonuclease ToolKit for Mouse Genome Editing |
2 |
| Perspectives of Sickle Cell Disease Stakeholders on Heritable Genome Editing |
2 |
